Radafaxine (developmental code GW-353,162; also known as '(2S,3S)-hydroxybupropion or (S,S)-hydroxybupropion') is a norepinephrine–dopamine reuptake inhibitor (NDRI) which was under development by GlaxoSmithKline in the 2000s for a variety of different indications but was never marketed. These uses included treatment of restless legs syndrome, major depressive disorder, bipolar disorder, neuropathic pain, fibromyalgia, and obesity. Regulatory filing was planned for 2007, but development was discontinued in 2006 due to "poor test results".
Radafaxine (developmental code GW-353,162; also known as '(2S,3S)-hydroxybupropion or (S,S)-hydroxybupropion') is a norepinephrine–dopamine reuptake inhibitor (NDRI) which was under development by GlaxoSmithKline in the 2000s for a variety of different indications but was never marketed. These uses included treatment of restless legs syndrome, major depressive disorder, bipolar disorder, neuropathic pain, fibromyalgia, and obesity. Regulatory filing was planned for 2007, but development was discontinued in 2006 due to "poor test results".
==Pharmacology==
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).